Rationale: Despite awareness of chronic obstructive pulmonary disease (COPD) treatment recommendations, uptake is poor. The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) spans 2010-2016, providing an opportunity to assess integration of 2011 Global Initiative for Obstructive Lung Disease (GOLD) treatment strategies over time in a large observational cohort study.
Chronic obstructive pulmonary disease (COPD) treatment recommendations are available to assist clinicians with selection of pharmacological therapy in COPD, but overall adherence to guideline recommendations remains limited (1, 2) . The most widely used therapeutic strategy is proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). This treatment strategy was initially published in 2001, with updates in 2011 and most recently in 2018 (3) (4) (5) . Despite the ubiquity of the GOLD treatment strategy, small observational studies report poor uptake of GOLD recommendations worldwide, with some studies demonstrating more than 50% of patients with COPD reporting treatments not consistent with guideline recommendations (1, (6) (7) (8) (9) (10) (11) (12) . There is little information on how alignment with treatment recommendations changes over time or on factors associated with overuse and underuse. Identifying and describing patient populations who are receiving suboptimal medication regimens can improve uptake of published treatment recommendations and overall COPD care.
The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) is a large, multicenter, observational cohort study of current and former smokers with extensive data regarding physiologic status, clinical parameters, and medication use (13) . SPIROMICS collected data from 2010 through 2016, permitting a unique opportunity to analyze associations between demographic factors and alignment with treatment recommendations, as well as how this alignment changed over time. Given 2011 GOLD treatment strategies (5) were used as the standard for diagnosis and management of COPD at the time of SPIROMICS data collection, the present analysis examines the alignment of medication use in SPIROMICS with 2011 GOLD recommendations. Some of the results of these studies were previously presented in the form of an abstract (14) .
Methods

Study Cohort
SPIROMICS is a multicenter cohort study with recruitment from 12 clinical centers and including former and current smokers (.20 pack-years) with and without COPD and nonsmoking control subjects (13) . Participant recruitment occurred through referrals from physicians at each clinical center, community-based recruitment in locations where individuals were seeking medical care (i.e., doctors' offices, pulmonary rehabilitation clinics), or selfreferrals. The analytical cohort for this study is limited to SPIROMICS participants with spirometry-defined COPD at the time of SPIROMICS visit (defined as postbronchodilator ratio of forced expiratory volume in 1 s [FEV 1 ] to forced vital capacity [FVC] ,0.70) with complete 2011 GOLD categorization (5) and medication use data at the baseline visit. All participants provided written informed consent, and institutional review boards at each For the purpose of analysis, alignment with treatment recommendations at each visit was defined as alignment of the participant's prescribed regimen to either first-or second-line GOLD recommendations of inhaled medications only (Table 1) . For GOLD-A, first-line therapy was as-needed use of short-acting anticholinergic agents (SAMA) or shortacting b-agonists (SABA). First-line pharmacologic therapy for GOLD-B Table 1 . Underuse was defined as use of less medication than allotted for a specific GOLD class. GOLD-B participants were defined as reporting underuse if they lacked long-acting maintenance therapy, such as LAMA or LABA, or lacked long-acting maintenance therapy, such as LAMA or LABA. For GOLD-B participants, use of ICS monotherapy was categorized as underuse. Both GOLD-C and GOLD-D underuse was defined by no maintenance therapy or use of LABA or ICS monotherapy. Overuse was defined as use of more medications than recommended for a specific GOLD classification. For GOLD-A, overuse included treatment with any ICS, combination ICS and LABA, combination of ICS and LAMA, combination of LAMA and LABA, or LAMA/ LABA/ICS therapy. GOLD-B overuse included treatment with any ICS-containing regimen (excluding ICS monotherapy, because this was classified as underuse). For GOLD-C participants, overuse was defined as combination of LAMA and ICS or use of LAMA/LABA/ICS. Analyses were conducted to examine the impact of income, education, and prior history of physician-diagnosed asthma on alignment with GOLD recommendations. Secondary analysis of alignment with 2017 GOLD recommendations was also conducted.
Statistical Methods
Baseline differences in demographic and clinical factors between cohort participants, stratified by alignment with recommendations, were assessed using chi-square tests (categorical variables) or analysis of variance (ANOVA) (continuous variables). Differences in medication use patterns at baseline, stratified by alignment and by treatment, were assessed via chi-square tests using Fisher's exact test to account for low frequency counts. Change in alignment over time was assessed among participants with complete follow-up data with the 'PTREND' STATA module, calculating chi-square test results for departure from the trend line of alignment over visits. To reduce the risk of type I error related to multiple comparisons, a Bonferronicorrected P value less than 0.002 (derived from the largest set of simultaneous comparisons [n = 22]) was used to define statistical significance in all comparisons. All analyses were completed with Stata 15.0 software (StataCorp).
Results
Participant Characteristics
The total SPIROMICS cohort (N = 2,974) included 1,831 individuals with spirometryconfirmed COPD (FEV 1 /FVC, ,0.7). The analytical cohort in the present study included 1,721 participants with spirometryconfirmed COPD and complete baseline medication use and 2011 GOLD categorization data, representing 94% of participants with COPD in SPIROMICS (see Figure E1 in the online supplement). The average age was 65.2 years; 58% were male; 81% were white; and 34% were current smokers ( Table 2) . At baseline, 22% of participants were classified as GOLD-A, 39% as GOLD-B, 4% as GOLD-C, and 35% as GOLD-D. Distribution of race was similar among GOLD categories; however, all other demographic and clinical characteristics were different among GOLD categories. GOLD-A participants were oldest (67.7 6 7.3 yr), whereas GOLD-D participants were youngest (63.8 6 7.9 yr). GOLD-A participants had the highest proportion of women (67%), whereas GOLD-C had the lowest proportion of women (41%). The GOLD-B cohort had the highest prevalence of current smokers (45%), whereas GOLD-C had the lowest prevalence of current smokers (19%). Lung function was lowest in GOLD-D (FEV 1 percent predicted, 39 6 15%) and highest in GOLD-A (FEV 1 percent predicted, 78.8 6 16%). Of the total cohort, 66% had mild to moderate airflow obstruction. As expected, higher proportions of GOLD-A and GOLD-B participants (90% and 80%, respectively) than GOLD-C and GOLD-D participants (61% and 47%, respectively) had no exacerbations. Of the total cohort, 81% reported having a physician diagnosis of either COPD, chronic bronchitis, or COPD, with GOLD-D participants being most likely to report any of these diagnoses. Only 57% of GOLD-A participants reported a diagnosis of either COPD, chronic bronchitis, or emphysema.
Baseline medication use is summarized in Figure E2 and Table E1 . At baseline, 27% of the entire cohort reported not using any inhaler (short-acting or maintenance), whereas 37% reported no long-acting maintenance inhaler use. The most prevalent maintenance inhaler use among GOLD-A and GOLD-B participants was a combination of LABA/ICS (10% and 20%, respectively), whereas triple therapy with 
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LAMA/LABA/ICS was the most common in GOLD-C and GOLD-D participants (37% and 43%, respectively). Of the total cohort, 4% reported ICS monotherapy as their only maintenance inhaler. Oral glucocorticoid use was uncommon in the cohort (4%), with increasing use in GOLD-C and GOLD-D participants. Specifically, glucocorticoid use was reported in 0.5% of GOLD-A participants, 1% of GOLD-B participants, 5% of GOLD-C participants, and 8% of GOLD-D participants.
Overall Alignment with 2011 GOLD Recommendations
At baseline, only 52% of overall participants' regimens aligned with GOLD first-/secondline treatment recommendations ( Figure 1 ), with lowest alignment in GOLD-B (14%) and GOLD-C (33%). Highest alignment with recommendations was among GOLD-A and GOLD-D (77% and 80%, respectively) in the overall cohort. As seen in Table 3 , age, sex, and race did not differ between participants whose treatment aligned with GOLD recommendations compared with those whose treatment did not. Participants with regimens not aligning with recommendations had better lung function (FEV 1 percent predicted, 66% vs. 56%; FVC percent predicted 92% vs. 85%; P , 0.01 for both comparisons). These participants were also more likely to be current smokers (41% vs. 28%; P , 0.001) and to report no exacerbations in the prior 12 months (78% vs. 63%; P , 0.001). Participants with regimens not aligning with recommendations reported less severe dyspnea (mMRC score >2; 29% vs. 35%) but worse overall COPD control (CAT score >10; 83% vs. 64%). There was no difference in self-report of either COPD, chronic bronchitis, or emphysema. Baseline maintenance inhaler use among the 833 participants with regimens not aligning with GOLD recommendations is summarized in Figure E3 and Table E2 . A total of 29% reported no short-acting or maintenance inhalers, and 45% reported no maintenance inhaler use. The most prevalent regimen of both GOLD-A and GOLD-B recommendation-nonaligned participants was LABA/ICS (45% and 23%, respectively).
The most prevalent regimen of GOLD-C recommendation-nonaligned participants was LAMA/LABA/ICS (56%). Among nonaligned GOLD-D participants, 73% reported no maintenance inhaler use, with 19% reporting LABA monotherapy use.
There was a wide range of alignment across the 13 study sites, ranging from 33% to 69%. This difference, when assessed by ANOVA, was not statistically different (P = 0.91).
Underuse versus Overuse
Among participants whose treatment did not align with recommendations, 449 (54%) were due to underuse and 384 (46%) were due to overuse (Figure 2 ). Among nonaligned participants, overuse was seen in 100% of GOLD-A participants, 46% of GOLD-B participants, 60% of GOLD-C participants, and 0% of GOLD-D participants. Sex and race were similar between those reporting underuse versus those reporting overuse (Table 4) . Compared with the overuse group, members of the underuse group were more likely to be current smokers (49% vs. 31%; P , 0.001) and to have a greater proportion with severe obstruction as measured by FEV 1 (GOLD FEV 1 strata III/IV) (27% vs. 7%; P , 0.001). Participants with underuse also had worse 
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overall symptom control, defined as CAT score greater than or equal to 10 (96% vs. 69%; P , 0.001), despite a similar proportion with mMRC score greater than or equal to 2 (30% vs. 29%; P = 0.82), and a higher proportion had two or more exacerbations in the year before baseline visit (7% vs. 2%; P , 0.001). Given the increased symptoms and exacerbations, participants with underuse were also more likely to be classified as GOLD-C or GOLD-D (30% vs. 8%; P , 0.001). The underuse group was less likely to report a diagnosis of either COPD, chronic bronchitis, or emphysema (72% vs. 93%; P , 0.001) as well as asthma (19% vs. 32%; P , 0.001). Underuse was predominately driven by no long-acting inhaler (83%), followed by ICS monotherapy (14%) ( Table E3) . Inappropriate ICS-containing inhalers accounted for all of those classified with overuse in the recommendation-nonaligned participants, most commonly LAMA/ LABA/ICS (48%). When we compared the distribution of overuse and underuse among the nonaligned group, we again found a wide range of overuse across sites (0-63%), with no statistical difference by site observed by ANOVA (P = 0.26).
Change in Alignment with GOLD Recommendations over Time
A total of 431 participants (25% of the analytical cohort) had complete follow-up data for GOLD categorization and medication use. There were no substantial differences in baseline demographics and medication use between those with and without complete follow-up data (Tables E4  and E5 ). Average alignment with GOLD recommendations for GOLD-A and GOLD-D participants was 76% at the baseline visit, and it did not change with updated GOLD status in subsequent years (P = 0.72 and P = 0.52, respectively) ( Figure 3 and Table E6 ). Both GOLD-B and GOLD-C participants had a statistically nonsignificant but numerical increase in alignment over time (GOLD-B, 10-17%; GOLD-C, 36-55%).
Sensitivity Analysis
Ever reporting physician-diagnosed asthma was associated with greater nonalignment to recommendations (53% vs. 46%; P = 0.034). History of asthma in this COPD cohort was associated with greater prevalence of overuse than among participants without asthma (58% vs. 41%; P , 0.001). Among participants with overuse reporting asthma, 51% reported LABA/ICS use, whereas 38% reported LAMA/LABA/ICS use. This contrasts with the participants with COPD without asthma, in whom the most common regimen was LAMA/LABA/ICS (53%), followed by LABA/ICS (41%). The overall use of an ICS-containing regimen did not differ between participants with COPD with or without asthma (P = 0.47).
Among participants whose treatment did not align with recommendations, lower income was associated with underuse. Specifically, 59% of participants with annual income less than $35,000 reported underuse compared with 51% of participants with annual income of $35,000 or higher (P = 0.027). Similar trends were seen with an income threshold of $50,000 (P = 0.05). There was no difference in alignment with recommendations when stratified by attained education level (P = 0.316). In addition, in the participants whose treatment did not align with recommendations, there was no difference of education level for overuse or underuse.
When we compared GOLD categorization between 2011 and 2017 publications, we observed that 72% of participants remained within the same GOLD category between the two definitions. 
Discussion
In this analysis of a large cohort of individuals with COPD participating in an observational cohort study, nearly 50% reported inhaler regimens that do not align with first-or second-line recommendations present at the time of data collection. Regimens not aligning with GOLD recommendations were evenly split between overuse and underuse. Underuse was primarily due to lack of maintenance inhalers, whereas overuse was due to inappropriate use of ICS-containing regimens. Aside from GOLD-B participants, overall alignment with recommendations did not change during follow-up. These findings highlight the lack of substantial uptake of published recommendations and the relatively stable treatment patterns for COPD over time.
The GOLD recommendations are internationally recognized as the standards 
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for COPD diagnosis and treatment. Despite this ubiquity, nonadherence to both diagnostic and treatment recommendations are prevalent (1, 6, 7, 9) . Prior studies have identified some barriers to poor uptake, including provider familiarity and time constraints (8, 18) . To our knowledge, this is one of the largest analyses examining factors associated with overuse and underuse in a well-characterized COPD population, as well as the largest to examine change in alignment with recommendations over time. We found that alignment with recommendations was largely unchanged from reports examining 2007 GOLD guidelines (7), despite increased awareness and publications surrounding the GOLD recommendations over the last decade. GOLD-B and GOLD-C participants had the highest rates of recommendation nonalignment. Prior studies have suggested that the complexity of GOLD assessments may impact alignment with recommendations (19) . Using the 2011 GOLD guidelines, classification into a group requires both spirometry and symptoms. Spirometry is frequently not obtained (8) , which may lead to misclassification. Although all SPIROMICS participants underwent spirometry within the context of research visits, providers prescribing inhalers may not have obtained spirometry. In addition, the 2011 recommendations did not include guidance on stepping up or stepping down therapy, which may have led to persistent nonalignment with treatment strategies (20) .
Among the participants not aligning with recommendations, those who reported underuse were more likely to have more severe obstruction (GOLD III/IV), be more symptomatic, and have a higher proportion of COPD exacerbations. The association between underuse and more severe disease burden has several potential explanations. Those with underuse were less likely to report a diagnosis of obstructive lung disease, raising the possibility that these patients either were not being diagnosed or were not aware of their diagnoses. Alternatively, the higher burden of symptoms and exacerbations among these participants may be underrecognized by providers, therefore leading to underuse. Without use of objective scales, physicians are frequently unable to properly identify symptoms most affecting their patients (21) . Participants reporting underuse were more likely to be current smokers, so providers may have attributed symptoms to smoking rather than to COPD. Similarly to other studies (7, 10) , the majority of participants with underuse lacked maintenance inhalers. Moreover, nearly one-third of these participants did not report any inhaler use (either short or long acting). The lowest income group was associated with underuse, suggesting that medication cost may contribute to nonalignment with published treatment strategies. These findings differ from those of Nishi and colleagues, who observed that patients with COPD with dual eligibility for Medicare and Medicaid are more likely to use maintenance inhalers, likely owing to a reduced copay burden (22) . SPIROMICS did not capture insurance status, limiting the ability to determine how this factor may be impacting alignment with guidelines. These symptomatic participants reporting underuse highlight a group that, if appropriately treated, could have improvement of symptom burden.
Participants reporting overuse were more likely to have mild obstruction 
(GOLD I/II), and all were on an ICS-containing regimen. ICS-containing regimens in COPD are indicated for GOLD-C or GOLD-D COPD (4, 5) . A recent analysis has shown that more than one-third of those classified as GOLD-A and over half of those classified as GOLD-B for inhaler therapy are inappropriately prescribed ICS regimens (23) . In that analysis, ICS/LABA therapy was the initial treatment choice for over 50% of patients. Similarly, we found that over 50% of all participants were prescribed ICScontaining regimens, and 92% of overuse participants were in GOLD-A or GOLD-B. Given the prevalence of asthma in this group with overuse, the ICS inhaler regimens may reflect treatment for asthma or asthma-COPD overlap. The treatment paradigm for asthma-COPD overlap has yet to be elucidated (24) . The overall use of ICS did not differ between the overusing participants with and without asthma, and it remains unclear if ICS could be an appropriate treatment for these participants.
Another reason for overuse with ICS may be related to combination medication availability. For the first two years of this study, ICS/LABA combined inhalers were the only long-acting combination inhalers available (25) . Nevertheless, although overuse may provide symptomatic benefits, therapies are not risk free, because there are many known side effects of ICS, including thrush and increased risk of pneumonia (26) .
Among the 25% of the analytical cohort with complete follow-up data, failure to align with recommendations was largely stable over the duration of follow-up in SPIROMICS. Given that there were no guidelines for stepping down therapy in 2011, many overuse participants may have been stepped up to achieve disease control and, once adequately controlled on ICS, may have been recategorized as GOLD-A or GOLD-B with overuse due to ICS therapy. In our analysis, patients with overuse were less symptomatic, which may dissuade practitioners from stepping down therapy once symptoms are controlled. Prior studies have described inertia among healthcare providers regarding changing current practices (27) . A recent audit evaluating treatment of COPD in outpatient settings showed that at follow-up visits, providers are most likely to keep the current regimen (64.8%) or step-up therapy (17.5%), whereas only 9.7% of visits involved stepped-down therapy (20) . A smaller study in Hong Kong showed that over three visits, less than one-third of patients had changes in pharmacologic therapy, and the primary reason for change was insufficient disease control (10) .
This study has several limitations. Data collection for exacerbations, smoking history, and medication use were obtained via self-report, increasing the chance for information and recall bias. Medication prescriptions were not verified with pharmacy records. Participants' accuracy of reporting medications may have increased over serial study visits (Hawthorne effect). In addition, there are no data on the type of providers, difference in prescribing practices among pulmonologists and primary care physicians, appropriate inhaler technique, and influence of pharmaceutical marketing forces, all of which may impact alignment with treatment recommendations. The GOLD recommendations, although widely cited and used to inform treatment, are limited in the strength of evidence supporting some treatment recommendations (5). Although our analysis was not designed to assess the validity of GOLD recommendations, the degree of uncertainty in some GOLD recommendations is a limitation impacting our analysis. This analysis was done using a cohort of patients self-selected to participate in SPIROMICS and therefore may bias toward more severe and symptomatic groups, decreasing generalizability to the COPD population as a whole. Despite these limitations, the robust and standardized data collection within a large COPD cohort representing the full spectrum of COPD provides a unique opportunity to assess integration of published COPD treatment strategies over time and explore factors related to failure to align with those recommendations. These findings highlight the possibility of implementation sciences to improve guideline adherence in COPD treatment.
In conclusion, this analysis demonstrates that nearly half of individuals with COPD participating in an observational cohort study reported inhaler regimens not aligning with available treatment recommendations. Overuse and underuse of COPD treatment were equally prevalent and persisted over time, highlighting the need to reassess patienttailored treatment strategies regularly. Given the changing landscape of classifying and treating patients with COPD, improvement of dissemination and uptake of published recommendations have the potential to improve care for patients with COPD. n Author disclosures are available with the text of this article at www.atsjournals.org. SPIROMICS participants and participating physicians, investigators and staff for making ORIGINAL RESEARCH
